Company
United StatesPublic company, NASDAQ: URGNUroGen Pharma, Inc. (NASDAQ: URGN), Princeton, NJ – FDA Inspections
Inspection records and compliance data for UroGen Pharma, Inc. in Princeton, New Jersey. 1 FDA inspection on record, last inspected December 16, 2024. Publicly traded as NASDAQ: URGN.
Company Profile
This profile covers UroGen Pharma, Inc. based in Princeton, New Jersey, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected December 16, 2024.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| December 16, 2024 | Not classified | Human Drugs | 1258252 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
UroGen Pharma, Inc.
Stock ticker
URGN
Exchange
NASDAQ
Share price
$25.72
Market cap
$1.3B
Price as of
November 6, 2026
FEI Number
3017168266
Address
400 Alexander Park Fl 4, Princeton, New Jersey 08540, United States
Country
United States
ID: a8de4933-996d-4d0f-97bf-e6fefc61be63